The Korean DRAM memory supplier and Micron’s main competitor released its results for Q2 2026. Despite extremely strong profit growth, the company suffered a valuation drop of as much as 9%.
Key metrics
- Revenue: The market expected about ₩84 billion, but the company delivered “only” ₩79.3 billion.
- Despite the disappointment, it is still up 257% year over year.
- Operating profit: Management reported ₩60.54 billion versus expectations of about ₩64 billion.
- That is a staggering 557% year-over-year increase, but still “as much as” 5% below consensus.
- Margin: The only clear reassurance for investors may have been the operating margin, which nevertheless met expectations, reaching 76.3% (up about 5 percentage points quarter over quarter).
Despite mild disappointments in the headline financial figures, there are reasons for optimism in the sales data.
- DRAM and NAND sales (quarter over quarter) rose by several to low double digits, with average price increases of 30% to 50%, depending on the segment.
- Enterprise-class SSD sales doubled quarter over quarter.
- The most mixed area is also the most promising segment: HBM4 memory. The company is currently still in the “final stretch” toward mass production, at least based on management’s assurances.
- Delays in this segment are clearly weighing on results and sentiment.
- Another perceived issue may be the company’s cash position, not its size, but rather the lack of transfers to shareholders.
- Management promised a cash distribution plan for shareholders by year-end, but has not provided specifics.
Guidance
For Q3, management is guiding for 10% DRAM volume growth (q/q) and a similar increase in NAND, accelerated HBM4 production, and CAPEX not exceeding ₩50 billion. These declarations are slightly below investor expectations, but imply only moderate pricing pressure.
Conclusion
The company’s results were objectively good, even very good. But in the current market context, “good” is not enough. A key concept for valuing “hyper-growth” companies, which currently include SK Hynix and Micron, is the so-called terminal value.
With growth expectations in the hundreds of percent and high valuation multiples, even a small miss versus expectations implies increasing (nominal) differences over time in the company’s implied terminal value.
The biggest issue with this concept, and a sort of consolation for shareholders, is that this mechanism no longer fully explains the share price reaction to the results, which may indicate an irrational nature of the sell-off. A sell-off driven more by sentiment or speculation than by real operational or strategic problems.
It would be very optimistic, if not naive, to expect the company to maintain its current growth pace over several years. However, the current share price already reflects a meaningful amount of risk regarding the quality of future earnings releases.
SK Hynix Price vs EPS Expectations
Looking at the relationship between the market’s EPS consensus and the share price, one can see that the price has already pulled back to the late March/early April level, even though results remain multiples higher and should, at least for some time, continue their hyperbolic growth.
Technical and valuation view:
- P/E is currently about 13.
- Forward P/E is currently just under 4.
- PEG (P/E divided by forecast EPS growth rate) is about 0.1.
- For context, values below 1 imply a stock that is “cheap” relative to its growth rate.
- Technically, RSI around ~35 indicates oversold levels.
France Challenges Palantir, Market Reacts.
The semiconductors sell-off continues 📉
US OPEN: Deeper sell-off and a SaaS rebound
ASML sell-out: Dreams and rumors will not break the monopoly
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.